Related Experiment Video
Updated: Jun 2, 2026
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
Published on: September 26, 2022
A novel DC therapy with manipulation of MKK6 gene on nickel allergy in mice
Megumi Watanabe1, Naozumi Ishimaru, Meinar Nur Ashrin
1Department of Oral Molecular Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Background:
Although the activation of dermal dendritic cells (DCs) or Langerhans cells (LCs) via p38 mitogen-activated protein kinase (MAPK) plays a crucial role in the pathogenesis of metal allergy, the in vivo molecular mechanisms have not been identified and a possible therapeutic strategy using the control of dermal DCs or LCs has not been established. In this study, we focused on dermal DCs to define the in vivo mechanisms of metal allergy pathogenesis in a mouse nickel (Ni) allergy model. The effects of DC therapy on Ni allergic responses were also investigated.
Methods And Finding:
The activation of dermal DCs via p38 MAPK triggered a T cell-mediated allergic immune response in this model. In the MAPK signaling cascade in DCs, Ni potently phosphorylated MAP kinase kinase 6 (MKK6) following increased DC activation. Ni-stimulated DCs could prime T cell activation to induce Ni allergy. Interestingly, when MKK6 gene-transfected DCs were transferred into the model mice, a more pronounced allergic reaction was observed. In addition, injection of short interfering (si) RNA targeting the MKK6 gene protected against a hypersensitivity reaction after Ni immunization. The cooperative action between T cell activation and MKK6-mediated DC activation by Ni played an important role in the development of Ni allergy.
Conclusions:
DC activation by Ni played an important role in the development of Ni allergy. Manipulating the MKK6 gene in DCs may be a good therapeutic strategy for dermal Ni allergy.
Insights
Nickel allergy involves dermal dendritic cell (DC) activation via p38 MAPK. Targeting MKK6 in DCs offers a potential therapeutic strategy for nickel allergy by modulating immune responses.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- Metal allergy pathogenesis involves dermal dendritic cell (DC) activation via p38 mitogen-activated protein kinase (MAPK).
- In vivo molecular mechanisms and therapeutic strategies for metal allergy remain underexplored.
- This study investigates dermal DCs in a mouse nickel (Ni) allergy model.
Purpose of the Study:
- To define in vivo mechanisms of Ni allergy pathogenesis.
- To investigate DC-based therapeutic strategies for Ni allergy.
Main Methods:
- Utilized a mouse model of nickel allergy.
- Investigated p38 MAPK signaling cascade in dermal DCs.
- Examined the role of MAP kinase kinase 6 (MKK6) using gene transfection and siRNA.
- Assessed T cell activation and allergic immune responses.
Main Results:
- Ni exposure activated dermal DCs via p38 MAPK, triggering T cell-mediated allergic responses.
- Nickel potently phosphorylated MKK6 in DCs, enhancing DC activation and T cell priming.
- MKK6 gene-transfected DCs exacerbated Ni allergy, while MKK6 siRNA protected against hypersensitivity.
- Cooperative action between T cell activation and MKK6-mediated DC activation is crucial for Ni allergy development.
Conclusions:
- Dermal DC activation by Ni is a key factor in Ni allergy development.
- Modulating the MKK6 gene in DCs presents a promising therapeutic avenue for dermal Ni allergy.
